title: Early glomerular changes in rats with dietary-induced hypercholesterolemia.
abstract: Increasing evidence suggests that lipids may be important modulators of progressive glomerular injury. We previously reported the long-term glomerular changes in rats with dietary-induced hypercholesterolemia. In this work, we evaluated the early glomerular changes induced by hypercholesterolemia that precede the development of glomerulosclerosis. In cholesterol-fed rats, an early macrophage influx was observed. This was associated with an increase in glomerular size, mesangial matrix expansion, lipid deposits, and foam cell formation. Immunohistochemical techniques showed that type IV collagen, fibronectin, and laminin were increased in cholesterol-fed rats. The mRNA expression for the alpha 1 chain of type IV collagen and an inhibitor of type IV collagenase were increased, suggesting that both increased synthesis and reduced degradation may be involved in cholesterol-induced mesangial matrix accumulation. The glomerular mRNA expression of transforming growth factor-beta 1 was also upregulated, suggesting that transforming growth factor-beta 1 could be an important mediator for mesangial matrix accumulation in hypercholesterolemic states. The early cholesterol-induced changes in the glomerulus are reminiscent in many respects to the process leading to glomerulosclerosis in the vessel wall.
authors.affiliation: Department of Medicine, University of Minnesota Medical School, Hennepin County Medical Center, Minneapolis 55439, USA.
authors.forename: C
authors.initials: C
authors.lastname: Guijarro
authors.forename: B L
authors.initials: BL
authors.lastname: Kasiske
authors.forename: Y
authors.initials: Y
authors.lastname: Kim
authors.forename: M P
authors.initials: MP
authors.lastname: O'Donnell
authors.forename: H S
authors.initials: HS
authors.lastname: Lee
authors.forename: W F
authors.initials: WF
authors.lastname: Keane
mesh_terms: D000818:Animals; D015152:Blotting, Northern; D002791:Cholesterol, Dietary / Q000008:administration & dosage / Q000009:adverse effects*; D003094:Collagen / Q000235:genetics / Q000378:metabolism; D005109:Extracellular Matrix / Q000473:pathology; D005353:Fibronectins / Q000378:metabolism; D005455:Fluorescent Antibody Technique; D005487:Foam Cells / Q000473:pathology; D005920:Glomerular Mesangium / Q000473:pathology; D006023:Glycoproteins / Q000378:metabolism; D006937:Hypercholesterolemia / Q000209:etiology / Q000378:metabolism / Q000473:pathology*; D007678:Kidney Glomerulus / Q000378:metabolism / Q000473:pathology*; D007797:Laminin / Q000378:metabolism; D008264:Macrophages / Q000473:pathology; D061965:Matrix Metalloproteinase Inhibitors; D016133:Polymerase Chain Reaction; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D019714:Tissue Inhibitor of Metalloproteinases; D016212:Transforming Growth Factor beta / Q000235:genetics; D015854:Up-Regulation
chemical_list: D002791:Cholesterol, Dietary; D005353:Fibronectins; D006023:Glycoproteins; D007797:Laminin; D061965:Matrix Metalloproteinase Inhibitors; D012333:RNA, Messenger; D019714:Tissue Inhibitor of Metalloproteinases; D016212:Transforming Growth Factor beta; D003094:Collagen